Research and analysis

COVID-19 therapeutic agents: technical briefings

Technical briefing documents on coronavirus (COVID-19) therapeutic agents.

Documents

COVID-19 therapeutic agents: technical briefing 4

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

COVID-19 therapeutic agents: technical briefing 3

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

COVID-19 therapeutic agents: technical briefing 2

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

COVID-19 therapeutic agents: technical briefing 1

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

The UK Health Security Agency (UKHSA) surveillance of the use of COVID-19 therapeutics in individuals who are eligible to receive them, and the potential resistance to therapeutics, was stood down on 31 August 2023.

Previous technical briefings are still available on this page and annual updates via the English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) report will be provided.

This surveillance activity does not impact individuals’ eligibility or access to therapeutics. Refer to the most recent government advice on eligibility for and access to COVID-19 therapeutics from Highest-risk patients eligible for new COVID-19 treatments: a guide for patients on GOV.UK.

Updates to this page

Published 21 January 2022
Last updated 31 August 2023 + show all updates
  1. Added details about end of programme with information on further updates.

  2. Added technical briefing 4.

  3. Added technical briefing 3.

  4. Added technical briefing 2.

  5. First published.

Sign up for emails or print this page